Stock Quote
Celgene Corporation (CELG.O) (Nasdaq)
$55.75
25 Nov 2009
+0.69%
$55.75
--
2,181,273
$55.80
$55.17
$58.31
$36.90
0.51
2,736,189
CELG.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Barer, Sol | Chairman of the Board, Chief Executive Officer | 8,525,090 |
| Hugin, Robert | President, Chief Operating Officer, Director | 5,158,400 |
| Gryska, David | Chief Financial Officer, Senior Vice President | 2,138,500 |
Profile
Celgene Corporation is an integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is involved in research in several scientific areas that may deliver... Full Description
Company Address
Celgene Corporation
86 Morris Avenue
Summit NJ 07901
P: +1908.6739000
F: +1732.2714184
86 Morris Avenue
Summit NJ 07901
P: +1908.6739000
F: +1732.2714184
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Amgen, Inc. | $57.08 | +0.28 |
| AstraZeneca plc | £2,732.00 | -46.00 |
| Biogen Idec Inc. | $47.45 | +0.07 |
| CELG.O | Industry | |
|---|---|---|
| P/E(TTM) | 70.68 | 13.09 |
| P/S(TTM) | 10.02 | 31.15 |
| ROI(TTM) | 8.78 | 2.44 |
| ROE(TTM) | 9.70 | 3.70 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.60 |
| EPS Est. (Current Year) | 2.04 |
| Total Revenue | $695.14M |
| Net Income | $216.82M |
| EPS | $0.46 |
